{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:28:58Z","timestamp":1780108138694,"version":"3.54.0"},"reference-count":24,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["SIP20\u2010004"],"award-info":[{"award-number":["SIP20\u2010004"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The Children's Oncology Group Guidelines recommend a cardiacechocardiogram, or comparable functional imaging, following therapy completion in survivors of childhood\/adolescent cancers exposed to anthracyclines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using the 2009\u20132019\u2009Merative\u2122 MarketScan\u00ae Commercial Database, we examined real\u2010world utilization of cardiac testing among 1609 anthracycline\u2010treated survivors of childhood\/adolescent cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cumulative incidence of receiving an initial cardiac test by 5.25\u2009years from the index date (six months after end\u2010of\u2010therapy) was 62.3% (95% CI\u2009=\u200957.5%\u201366.7%), with median time to initial test being 2.7\u2009years (95% CI\u2009=\u20092.5%\u20133.1%). Young adults (18\u201328\u2009years) were less likely than children (\u226417\u2009years) to receive cardiac testing (hazard ratio [HR]\u2009=\u20090.42, 95% CI\u2009=\u20090.3%\u20130.49%). More likely to receive cardiac testing were survivors receiving hematopoietic stem cell transplantation versus chemotherapy only (HR\u2009=\u20092.23, 95% CI\u2009=\u20091.63%\u20133.03%), and survivors with bone or soft tissue versus hematologic cancer (HR\u2009=\u20091.64, 95% CI\u2009=\u20091.30%\u20132.07%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Nearly 40% of anthracycline\u2010treated survivors of childhood\/adolescent cancers had not received cardiac testing within 5.25\u2009years post\u2010index date, with young adults least likely to receive a test.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6801","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T20:59:01Z","timestamp":1702155541000},"page":"22056-22061","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Utilization of cardiac tests in anthracycline\u2010treated cancer survivors differs between young adults and children: A claims\u2010based analysis"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3025-3984","authenticated-orcid":false,"given":"Xu","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Pediatrics Emory University School of Medicine  Atlanta Georgia USA"},{"name":"Aflac Cancer &amp; Blood Disorders Center, Children's Healthcare of Atlanta  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1097-3300","authenticated-orcid":false,"given":"Xin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences University of Virginia School of Medicine  Charlottesville Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lipscomb","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Rollins School of Public Health Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Chow","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine and Fred Hutchinson Cancer Research Center  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"Mertens","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Emory University School of Medicine  Atlanta Georgia USA"},{"name":"Aflac Cancer &amp; Blood Disorders Center, Children's Healthcare of Atlanta  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Emory University School of Medicine  Atlanta Georgia USA"},{"name":"Aflac Cancer &amp; Blood Disorders Center, Children's Healthcare of Atlanta  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3634"},{"key":"e_1_2_10_3_1","unstructured":"Children's Oncology Group (COG).Long\u2010Term Follow\u2010Up Guidelines for Survivors of Childhood Adolescent and Young Adult Cancers.2018. Children's Oncology Group Statistics and Data Center. Accessed February 1 2022. Available at:http:\/\/www.survivorshipguidelines.org\/pdf\/2018\/COG_LTFU_Guidelines_v5.pdf"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70409-7"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01764"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-017-0634-z"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01825"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.3493"},{"key":"e_1_2_10_9_1","unstructured":"AdamsonDM ChangS HansenLG.Health Research Data for the Real World: The MarketScan Databases.2006. Accessed December 7 2019.http:\/\/patientprivacyrights.org\/wp\u2010content\/uploads\/2011\/06\/Thomson\u2010Medstat\u2010white\u2010paper.pdf"},{"key":"e_1_2_10_10_1","unstructured":"IBM Watson Health.IBM MarketScan Research Databases for life sciences researchers.https:\/\/www.ibm.com\/us\u2010en\/marketplace\/marketscan\u2010research\u2010databases"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac049"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2017.11.063"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3744"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100015"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/80.3.557"},{"key":"e_1_2_10_16_1","unstructured":"Children's Oncology Group (COG).Long\u2010Term Follow\u2010Up Guidelines for Survivors of Childhood Adolescent and Young Adult Cancer. Version 4.0.2013. Children's Oncology Group Statistics and Data Center. Accessed September 7 2019.http:\/\/www.survivorshipguidelines.org\/pdf\/COG%20LTFU%20Guidelines%20Archive\/Version%204.0\/COG_LTFU_Guidelines_v4%20(secured).pdf"},{"key":"e_1_2_10_17_1","unstructured":"Children's Oncology Group (COG).Long\u2010Term Follow\u2010Up Guidelines for Survivors of Childhood Adolescent and Young Adult Cancers. Version 3.0.2008. Children's Oncology Group Statistics and Data Center. Accessed January 20 2020.http:\/\/survivorshipguidelines.org\/pdf\/COG%20LTFU%20Guidelines%20Archive\/Version%203.0\/COG_LTFU_Guidelines_v3%20(secured).pdf"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0103"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2003.12.008"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005984"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000723"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-016-0522-y"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-015-0493-4"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-00748-x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.5400"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T08:55:40Z","timestamp":1705222540000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":24,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/cam4.6801"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6801","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"2023-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}